RELAPSE RATE OF VIVAX MALARIA WITH SHORTER DURATION OF ANTIRELAPSE TREATMENT IN IRAN

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

SALEHI MASOUD; ESMAEILZADEH M.

Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Zahedan Journal of Research in Medical Sciences Year:2002 | Volume:4 | Issue:2 Page(s): 99-106

Download Full-Text

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Verion

View:

1,307

Download:

Cites:

Information Journal Paper

Title

RELAPSE RATE OF VIVAX MALARIA WITH SHORTER DURATION OF ANTIRELAPSE TREATMENT IN IRAN

Author(s)

SALEHI MASOUD | ESMAEILZADEH M. | Issue Writer Certificate

Keywords

MALARIAQ3

PLASMODIUM VIVAXQ3

RELAPSEQ2

TREATMENTQ3

Abstract

Every year thousand of MALARIA cases mostly the vivax type Occur in Iran. The recommendation of WHO for antirelapes therapy of vivax MALARIA is the usage of primaquine (15mg daily) for 14 days but in area where G6PD deficiency rate is high 8 weeks therapy (each week 45 mg of primaquine) is recommended. Considering the fact that in Iran drug therapy of MALARIA is implemented by direct observation of health care workers, 8 weeks regime of antirelapes therapy of vivax is very expensive and in some situations impractical. In this study shorter duration of antirelapse therapy was compared to that of 8 weeks regimen. In 1996 and 1997 antirelapse therapy of vivax in Sistan and Baluchistan province in southeast of Iran was done with different regimes according to manpower and executive facilities. This is a cohort study that compare clinically and parasitologicaly RELAPSE of vivax MALARIA in 200 patients with one-week therapy, 200 patients with 2 weeks, 800 patients with 4 weeks and 500 patients with 8 weeks therapy by primaquine. Relapes rate of vivax MALARIA by each regime were 23.8%,13.2%,5.4% and 4.6% respectively .Relative risk of RELAPSE in comparison with 8 weeks regime were 5.2 ,2.9 and 1.2 respectively .Number need to therapy (NNT) were 5,12 and 125 .Interval of first RELAPSE varied between 6 to 52 weeks with mean of 28.8 weeks . The RELAPSE rate was not different by sex. The RELAPSE rate by 4 and 8 weeks regimes were low and there was not significant difference of RELAPSE rate in 4 and 8 weeks regimes. So in special situations we can use 4 weeks therapy instead of 8 weeks therapy.

Cites

References

No record.

Cite

APA: Copy

SALEHI, MASOUD, & ESMAEILZADEH, M.. (2002). RELAPSE RATE OF VIVAX MALARIA WITH SHORTER DURATION OF ANTIRELAPSE TREATMENT IN IRAN. ZAHEDAN JOURNAL OF RESEARCH IN MEDICAL SCIENCES (TABIB-E-SHARGH), 4(2), 99-106. SID. https://sid.ir/paper/84579/en

Vancouver: Copy

SALEHI MASOUD, ESMAEILZADEH M.. RELAPSE RATE OF VIVAX MALARIA WITH SHORTER DURATION OF ANTIRELAPSE TREATMENT IN IRAN. ZAHEDAN JOURNAL OF RESEARCH IN MEDICAL SCIENCES (TABIB-E-SHARGH)[Internet]. 2002;4(2):99-106. Available from: https://sid.ir/paper/84579/en

IEEE: Copy

MASOUD SALEHI, and M. ESMAEILZADEH, “RELAPSE RATE OF VIVAX MALARIA WITH SHORTER DURATION OF ANTIRELAPSE TREATMENT IN IRAN,” ZAHEDAN JOURNAL OF RESEARCH IN MEDICAL SCIENCES (TABIB-E-SHARGH), vol. 4, no. 2, pp. 99–106, 2002, [Online]. Available: https://sid.ir/paper/84579/en

Related Journal Papers